Spyre Therapeutics Inc (SYRE) Stock AnalysisSYRESpyre Therapeutics Inc

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, specializing in long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. The Company's pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. It is advancing a pipeline of monoclonal antibodies (mAbs) for the treatment of IBD and other immune-mediated diseases. The Company's pipeline includes its SKYLINE Phase II platform trial evaluating SPY001, SPY002, SPY003, and pairwise combinations thereof in subjects with moderately to severely active UC and its SKYWAY basket trial evaluating SPY072 in three rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). SPY001 is a highly potent, highly selective, and humanized monoclonal immunoglobulin G1 investigational antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD (UC and CD). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Spyre Therapeutics Inc is currently a hold. The stock is priced at $79.90, which is significantly lower than the average analyst price target of $123. However, the RSI is at 37.725, indicating that the stock is currently oversold, while the recent insider selling (up 796.31%) raises concerns about confidence in the stock's near-term performance. The company has shown strong long-term growth with a 240.14% increase over the past year, but recent earnings reports have shown significant losses, with a net income of -69 million in Q1 2026.